NBC Securities Inc. Has $1.10 Million Position in Gilead Sciences, Inc. (NASDAQ:GILD)

NBC Securities Inc. decreased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 1.0% during the 2nd quarter, Holdings Channel reports. The institutional investor owned 16,055 shares of the biopharmaceutical company’s stock after selling 159 shares during the quarter. NBC Securities Inc.’s holdings in Gilead Sciences were worth $1,101,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the company. Private Wealth Management Group LLC acquired a new position in Gilead Sciences in the fourth quarter valued at approximately $29,000. Palisade Asset Management LLC acquired a new position in shares of Gilead Sciences during the 1st quarter worth about $29,000. Sachetta LLC bought a new stake in shares of Gilead Sciences in the 4th quarter valued at about $30,000. Rakuten Securities Inc. acquired a new stake in shares of Gilead Sciences in the 4th quarter valued at approximately $33,000. Finally, Gladius Capital Management LP acquired a new position in Gilead Sciences during the fourth quarter valued at approximately $34,000. 83.67% of the stock is currently owned by institutional investors.

Insider Activity

In other news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $68.63, for a total value of $137,260.00. Following the completion of the transaction, the insider now owns 96,380 shares of the company’s stock, valued at approximately $6,614,559.40. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 0.16% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on GILD shares. Morgan Stanley reduced their price target on shares of Gilead Sciences from $80.00 to $78.00 and set an “equal weight” rating on the stock in a research report on Friday, April 26th. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a report on Friday, April 26th. HSBC upgraded Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 price objective for the company in a research report on Wednesday, April 24th. StockNews.com upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Saturday, April 27th. Finally, Maxim Group reduced their price target on shares of Gilead Sciences from $90.00 to $85.00 and set a “buy” rating for the company in a report on Wednesday, May 1st. Twelve analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $81.81.

Gilead Sciences Stock Up 1.8 %

GILD stock traded up $1.33 during mid-day trading on Thursday, reaching $75.33. The company had a trading volume of 4,189,595 shares, compared to its average volume of 7,359,059. The company has a market capitalization of $93.85 billion, a price-to-earnings ratio of 205.56, a PEG ratio of 3.37 and a beta of 0.18. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $87.86. The stock has a 50 day simple moving average of $69.39 and a two-hundred day simple moving average of $70.51. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.08 and a quick ratio of 0.94.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.